Cloperidone hydrochloride 

Cloperidone hydrochloride acts as an inhibitor and substrate of CYP2C9, with an IC₅₀ of 17.7 μM. Cloperidone hydrochloride exhibits enhanced cytotoxicity in cells expressing CYP2C9. It can be used in the research of sedative/hypnotic-related diseases^[1][2].

Cloperidone (0.3-100 μM; 6 min preincubation, 15 min incubation with substrate) hydrochloride potently inhibits recombinant CYP2C9 microsomes, with an IC₅₀ of 17.7 μM^[1].
Cloperidone (0-60 min) hydrochloride can be metabolized by recombinant CYP2C9 supersomes to produce a variety of distinct oxidative metabolites^[1].
Cloperidone (100 μM) hydrochloride exhibits enhanced cytotoxicity in HepG2 cells expressing CYP2C9, reducing cell viability to 40% of the baseline level^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

435.35

C₂₁H₂₄Cl₂N₄O₂

525-26-8

O=C1NC2=C(C(N1CCCN3CCN(CC3)C4=CC(Cl)=CC=C4)=O)C=CC=C2.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Goldwaser E, et al. Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9. PLoS Comput Biol. 2022 Jan 26;18(1):e1009820.  [Content Brief]

  [2]. Estrada E, et al. Designing sedative/hypnotic compounds from a novel substructural graph-theoretical approach. Journal of computer-aided molecular design. 1998 Nov;12(6):583-95.